“…While its value may have been overestimated in some areas, it is nevertheless a useful drug in the prevention and early intervention of SIRS, and therefore of laminitis. The clinical value of "low-dose Banamine," or what has been controversially termed the "anti-endotoxin dose," where flunixin meglumine is administered at a dosage of 0.25 mg/kg q8h, has been questioned, and in its place a dosage of 1.1 mg/kg q12h is recommended in the well-hydrated patient [2]. Flunixin meglumine is a nonselective inhibitor of the COX enzymes, and a potent inhibitor of COX-1.…”